Lung cancer study reveals hidden toll of muscle loss during targeted therapy
NCT ID NCT07559526
First seen May 08, 2026 · Last updated Jun 13, 2026 · Updated 12 times
Summary
This study looked at the nutrition and body composition of 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and strength to see how common malnutrition and muscle loss were, and how these affected quality of life. The goal was to gather information, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Complex of Vigo
Vigo, Pontevedra, 36312, Spain
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.